tiprankstipranks
Trending News
More News >
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
US Market

Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics

Compare
272 Followers

Total Valuation

Lantern Pharma has a market cap or net worth of $33.97M. The enterprise value is $28.39M.
Market Cap$33.97M
Enterprise Value$28.39M

Share Statistics

Lantern Pharma has 10,784,725 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,784,725
Owned by Insiders19.95%
Owned by Institutions14.95%

Financial Efficiency

Lantern Pharma’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is 516.01%.
Return on Equity (ROE)-0.98
Return on Assets (ROA)-812.66
Return on Invested Capital (ROIC)516.01%
Return on Capital Employed (ROCE)5.16
Revenue Per Employee0.00
Profits Per Employee-865.88K
Employee Count24
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Lantern Pharma is >-0.01. Lantern Pharma’s PEG ratio is -0.31.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio1.17
Price to Fair Value<0.01
Price to FCF-5.12
Price to Operating Cash Flow-5.13
PEG Ratio-0.31

Income Statement

In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -20.78B in profits. Earnings per share was -1.93K.
Revenue0.00
Gross Profit0.00
Operating Income-22.22B
Pretax Income-20.78B
Net Income-20.78B
EBITDA-20.59M
Earnings Per Share (EPS)-1.93K

Cash Flow

In the last 12 months, operating cash flow was -19.12M and capital expenditures -11.54K, giving a free cash flow of -19.13M billion.
Operating Cash Flow-19.12M
Free Cash Flow-19.13M
Free Cash Flow per Share-1.77

Dividends & Yields

Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.77
52-Week Price Change-27.40%
50-Day Moving Average3.42
200-Day Moving Average3.65
Relative Strength Index (RSI)47.11
Average Volume (3m)53.19K

Important Dates

Lantern Pharma upcoming earnings date is Aug 6, 2025, Before Open (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date

Financial Position

Lantern Pharma as a current ratio of <0.01, with Debt / Equity ratio of 0.09%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap0.00
Net Debt to EBITDA0.35
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Lantern Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Lantern Pharma EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.52.
EV to Sales0.00
EV to EBITDA-1.31
EV to Free Cash Flow-1.52
EV to Operating Cash Flow-1.52

Balance Sheet

Lantern Pharma has $19.72M in cash and marketable securities with $194.93K in debt, giving a net cash position of -$19.53M billion.
Cash & Marketable Securities$19.72M
Total Debt$194.93K
Net Cash-$19.53M
Net Cash Per Share-$1.81
Tangible Book Value Per Share$1.97

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.00
Price Target Upside686.16% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast-31.16%

Scores

Smart Score5
AI Score45
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis